Subgroups of paediatric acute lymphoblastic leukaemia might differ significantly in genetic predisposition to asparaginase hypersensitivity

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Kutszegi, Nóra ^a   Semsei, Ágnes F ^a   Gézsi, András ^a   Sági, Judit C ^a   Nagy, Viktória ^a   Csordás, Katalin ^a   Jakab, Zsuzsanna ^a   Lautner Csorba, Orsolya ^a   Gábor, Krisztina Míta ^b   Kovács, Gábor T ^a   Erdélyi, Dániel J ^a   Szalai, Csaba ^a,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ASPARAGINASE; ANTINEOPLASTIC AGENT; ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GALNT10 GENE; GENE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GRIA1 GENE; HUMAN; IMMUNOPHENOTYPING; MAGYAR (PEOPLE); MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ALLELE; COMPLICATION; GENETIC ASSOCIATION STUDY; GENETICS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ALLELES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 84948808423     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140136     Document Type: Article

References (32)

1. Garami M, Schuler D, Jakab Z. (2014) [Importance of the National Childhood Cancer Registry in the field of paediatric oncology care in Hungary]. Orv Hetil 155:732-739. doi: 10.1556/OH.2014.29918 PMID: 24796778
2. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, Lacour B, et al. (2004) Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study. Lancet 364:2097-2105. PMID: 15589307
3. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. (2014) Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL ICBFM 2002. J Clin Oncol 32:174-184. doi: 10.1200/JCO.2013.48.6522 PMID: 24344215
4. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. (2009) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 (vol 111, pg 4477, 2008). Blood 113:4478-4478.
5. Andrade AF, Borges KS, Silveira VS. (2014) Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. Clin Med Insights Oncol 8:95-100. doi: 10. 4137/CMO. S10242 PMID: 25210485
6. Avramis VI, Tiwari PN. (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1:241-254. PMID: 17717965
7. Kawedia JD, Rytting ME. (2014) Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14 Suppl: S14-17. doi: 10.1016/j.clml.2014.06.017 PMID: 25486949
8. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117:238-249. doi: 10.1002/cncr.25489 PMID: 20824725
9. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. (2005) Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 23:7161-7167. PMID: 16192600
10. Rizzari C, Conter V, Stary J, Colombini A, Moericke A, Schrappe M. (2013) Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 25 Suppl 1:S1-9. doi: 10.1097/CCO. 0b013e32835d7d85 PMID: 23380829
11. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, et al. (2000) Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 18:1525-1532. PMID: 10735901
12. Muller HJ, Boos J. (1998) Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97-113. PMID: 9768345
13. Narta UK, Kanwar SS, Azmi W (2007) Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61:208-221. PMID: 17011787
14. Shinnick SE, Browning ML, Koontz SE. (2013) Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. J Pediatr Oncol Nurs 30:63-77. doi: 10.1177/1043454212471728 PMID: 23380527
15. Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, et al. (2010) Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 88:191-196. doi: 10. 1038/clpt.2010.94 PMID: 20592726
16. Rajic V, Debeljak M, Goricar K, Jazbec J. (2015) Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. Leuk Lymphoma: 1-6.
17. Erdelyi DJ, Kamory E, Csokay B, Andrikovics H, Tordai A, Kiss C, et al. (2008) Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J 8:321-327. PMID: 17938643
18. Gezsi A, Lautner-Csorba O, Erdelyi DJ, Hullam G, Antal P, Semsei AF, et al. (2014) In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia. Pharmacogenomics J.
19. Bishop JR, Chae SS, Patel S, Moline J, Ellingrod VL. (2012) Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res 199:74-76. doi: 10.1016/j.psychres. 2012.03.048 PMID: 22534499
20. Magri C, Gardella R, Barlati SD, Podavini D, Iatropoulos P, Bonomi S, et al. (2006) Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample. Am J Med Genet B Neuropsychiatr Genet 141 B: 287-293. PMID: 16526023
21. Benjamini Y, Hochberg Y. (1995) Controlling the False Discovery Rate-a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57:289-300.
22. Storey JD. (2002) A direct approach to false discovery rates. Journal of the Royal Statistical Society Series B-Statistical Methodology 64:479-498.
23. Ma Q, Lu AY. (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63:437-459. doi: 10.1124/pr.110.003533 PMID: 21436344
24. Lombardi G, Dianzani C, Miglio G, Canonico PL, Fantozzi R. (2001) Characterization of ionotropic glutamate receptors in human lymphocytes. Br J Pharmacol 133:936-944. PMID: 11454668
25. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. (2003) Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol 170:4362-4372. PMID: 12682273
26. Ganor Y, Levite M. (2014) The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. J Neural Transm 121:983-1006. doi: 10.1007/s00702-014-1167-5 PMID: 24584970
27. Pacheco R, Oliva H, Martinez-Navio JM, Climent N, Ciruela F, Gatell JM, et al. (2006) Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol 177:6695-6704. PMID: 17082582
28. Pieters R, Appel I, Kuehnel HJ, Tetzlaff-Fohr I, Pichlmeier U, van der Vaart I, et al. (2008) Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood 112:4832-4838. doi: 10.1182/blood-2008-04-149443 PMID: 18805963
29. Egebjerg J, Kukekov V, Heinemann SF. (1994) Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. Proc Natl Acad Sci U S A 91:10270-10274. PMID: 7937939
30. Pagani F, Baralle FE. (2004) Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5:389-396. PMID: 15168696
31. Pagani M. (2010) The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 94:835-852, xiii. doi: 10.1016/j.mcna.2010.03.002 PMID: 20609866
32. Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, et al. (2015) Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood 126:69-75. doi: 10.1182/blood-2015-02-628800 PMID: 25987655